For HIV patients with high liver enzymes taking a placebo, losing visceral fat didn't lead to better liver enzyme levels.

HIV patients with high liver enzymes who lost visceral fat from tesamorelin kept their liver enzyme improvements for a full year even after stopping the drug, even though some fat came back.

Among HIV patients with high liver enzymes, 35% of those who lost at least 8% visceral fat from the drug had their ALT levels return to normal after six months, compared to 18% of those who didn't lose much fat.

HIV patients with belly fat and high liver enzymes who lost at least 8% visceral fat were more likely to have their ALT levels return to normal after 6 months than those who didn't lose that much fat.

HIV patients with belly fat and high liver enzymes had more visceral fat and less fat under the skin than those with normal liver enzymes.

HIV patients with belly fat and high liver enzymes who lose at least 8% of visceral fat see a bigger drop in AST levels than those who don't lose that much fat.